Business Wire

ADVA

13.1.2022 09:02:06 CET | Business Wire | Press release

Share
Equinix connects Antoni van Leeuwenhoek hospital with ADVA’s encrypted transport solution

ADVA (FSE: ADV) today announced that Equinix – the world’s digital infrastructure company – has deployed ADVA’s FSP 3000 open optical transport technology to provide Antoni van Leeuwenhoek, one of the Netherland’s leading hospitals, with encrypted dark fiber and fully managed services. Linking the healthcare provider’s data centers and facilities, the solution enables Equinix Managed Services to deliver secure Ethernet services up to 40GbE and highly reliable, low-latency Fibre Channel storage area network (SAN) connectivity up to 32Gbit/s. With ADVA’s ConnectGuard optical encryption technology ensuring robust data protection, the solution gives the hospital access to bandwidth-hungry applications and allows patient and medical research information to be securely collected, managed, analyzed and shared.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005540/en/

“By harnessing ADVA FSP 3000 technology and the support of the ADVA and TrueCom teams, we’re enabling Antoni van Leeuwenhoek hospital to transform its operations. With high-capacity, low-latency connectivity to its data centers, all protected by robust encryption at the optical layer, the hospital’s medics and support staff can leverage new applications and collaborate like never before to advance cutting-edge research and enhance patient care,” said Art de Blaauw, director of technology and innovation, Managed Services Solutions at Equinix. “It’s crucial for the healthcare industry that patient data is secure. ADVA’s ConnectGuard solution safeguards the network stack without adding latency or affecting throughput. That means medical practitioners can access critical information at any time, which is crucial for efficient processes and patient outcomes.”

Built on ADVA’s FSP 3000 open optical transport solution, the new network is capable of secure high-capacity transmission of Ethernet services up to 40GbE. With its agile, scalable and modular design, the FSP 3000 provides a truly flexible foundation, ready to expand and evolve as the needs of the healthcare provider change. The solution enables a high-speed SAN capable of transporting 32Gbit/s Fibre Channel, ensuring rapid access to patient information. This is key for healthcare professionals dealing with huge data sets. The infrastructure is comprehensively secured at the physical layer by ADVA FSP 3000 ConnectGuard™ , which is easy to operate and highly efficient, delivering the lowest cost per bit of any network encryption solution available today. ADVA’s partner TrueCom also played a key role in this project, providing installation and support, ensuring the new infrastructure met all the end customer’s requirements.

“We’re proud that our solution is now helping another major healthcare provider optimize its operations. Protecting the integrity and privacy of patients’ sensitive data couldn’t be more critical. That’s why our security technology is so important here. It ensures valuable data remains safe at every stage of its journey, while data-intensive applications continue to run,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “Approved by the German Federal Office for Information Security (BSI), our FSP 3000 ConnectGuard optical encryption ensures that patient records are protected by the most robust security methods available while adding virtually no delay.”

“There’s no doubt that the medical industry is at the forefront of the battle against cybercrime. Criminals see healthcare providers as treasure troves of valuable data that can easily be monetized. But thanks to our close collaboration with Equinix and ADVA, this hospital can be assured that its systems are secured,” said Dhieradj Ramanand, optical solutions sales manager at TrueCom. “With the ADVA FSP 3000 ConnectGuard optical security solution safeguarding data in motion right across the network, encrypted signals become worthless to a hacker. That’s why this technology is the last word in data security. It’s also the key to peace of mind for medical practitioners and their patients.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 08:00:00 CEST | Press release

A hybrid quantum-classical algorithm, executed end to end on IQM hardware, produced feasible schedules with Deutsche Bahn, the German rail operator, using a real operational dataset of 190 trips across five German cities. The approach runs on today’s hardware and is designed to improve automatically as quantum processors scale, offering enterprises a model for extracting value now, ahead of fault-tolerant computing. The collaboration reflects IQM’s push into enterprise adoption. The company has sold 24 quantum computers worldwide and listed on the Nasdaq Global Select Market and Nasdaq Helsinki in July 2026 under the ticker IQMX. IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.busines

Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 07:00:00 CEST | Press release

Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent la

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca

STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release

STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo

Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release

A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye